Failure Mode and Effects Analysis (FMEA)

Margaret Colquhoun

Consultant, ISMP Canada

Director of Pharmacy & Professional Practice, Markham Stouffville Hospital

What is Failure Mode and Effects Analysis (FMEA)?

Failure Modes and Effects Analysis (FMEA) is a systematic, proactive method for evaluating a process. What is Failure Mode and Effects Analysis (FMEA)?

A tool to:

 Analyze a process to see where it is likely to fail.

 See how changes you are considering might affect the safety of the process. 'FMEA can be employed before new services, processes, or products are purchased or implemented, to identify potential failure modes and so steps can be taken to avoid errors before they occur.'

'Failure Mode and Effects Analysis Can Help Guide Error-Prevention Efforts', Matthew Grissinger, RPh, P&T, January 2003 – Vol 28 No. 1

FMEA includes a review of:

Steps in the process

- Failure modes (What could go wrong?)
- Failure causes (Why would the failure happen?)
- Failure effects (What would be the consequences of each failure?)

'Emphasis on prevention may reduce risk of harm to both patients and staff.'

Failure Modes and Effects Analysis (FMEA), IHI and Quality Health Care.org, 2003

Failure Modes and Effects Analysis (FMEA) was developed outside of healthcare.



Step One:

Select a process to evaluate with FMEA

Step Two:

Recruit a multi-disciplinary team

(Be sure to include everyone who is involved at any point in the process)

Step Three:

Have the team meet together to list all the steps in the process

 Number every step in the process, and be as specific as possible.

Step Four:

Have the team list failure modes and causes

- List anything that could go wrong including minor and rare problems.
- Identify all possible causes for each failure mode.

R		ALLERGIES MERLIN SKLIPONI TU PASID PRETY KNOWN ALLER			- personal	
siversity Health Network			THE BURNES CHURCH AND	C. Carlos and Street Stre	1000	
Doctor's Order Sheet		< NSAIDs:			1000	
nesthesia/Acute Pain Service		(Choose one of the following or				
tient Controlled Analgesia (PCA) Orders		 Toradol (Kelozolac*) 15 m 			1.0	
ALLERGIES:		Celecosti (Calabrer') C Rolecosti (Viox*)				
I SUR MURONT NO KNOWN ALLERGIES		Call Acute Pain Service (AP				
KNOWN ALLERGIES (See of y)	NUMPER AND ADDRESS OF	a) Respiratory Rate less				
PHYSICIAN'S ORDER AND SIGNATURE	#0 1111 1111	b) Blood Pressure Syste	Ac less than 90 mmHg.			
		c) Pulse less than 50 be	ats per minute.			
While on PCA device, patient is to receive No further supplemental Narcotics unless			samnolent, difficult la rouse))	-	
pproved by the Anaesthesia/Acute Pain Service.			ol (eg: NRS greater than 4)			
PCADRUG		 If four hour limit of dru 	g dose is reached before 4 h	hours has etapsed.		
Morphine 2 mg/ml		7. If side effects of slow respirato	an order to contract the second	STOP SCA During		
Meperidine 10 mg/mil.		immediately and inform attend				
Hydromotphone 0.4 mg/mil.						
Other:		8. Two RN's will check and verify	the initial PCA settings and	I document on PCA Flowsheat		
PUMP SETTINGS		9 RN will check and verify PCA	setting every shift and docur	mant on PCA Flowsheet		
Dosemg tomg						
initial Lockout Interval min		10. (For TGH only) When toler	ating fluids well, discontin	nue PCA then start		
Four hour limit ma		a) Analgesia				
		b) Bowel Medications:				
MONITORING		Colace 100 mg po bid	tablets polig			
Respiratory Rate. Sedation Score q 2 h x 24hr. then q 4 h. Record on PCA. Flow She	ы.		mores he d			
TREATMENT OF SIDE EFFECTS:						
Have Nakxone (Narcan*) 0.4 mg/mL. Ampoule readily available at Nursing Station				A, call Anesthesia Rasidont og Slaff		
(Check 🗹 appropriate box(es) and complete orders as required		Anesthesia on call through locatin	9			
Dimentydniate (Gravol*) mg IVIM q 3 h pm for nausea/vomiting IV dose to be infused in 15 - 30 minutes.	-	PAGER NUMBERS:	TGH	TWH		
If Dimenhydrinate (Gravot*) ineffective, then give Granisatron (Kytal*) 1mg IV q 24	in	APS SUIT	416) 667 6095	416)667-3557		
xdoses for nausea/vomitting		ACNE	4161667-6035	415)567-3765		
Diphenhydramine (Benadryill)						
IV dose to be infused in 15 - 30 minutes		Anesthesia Resident	415)664-3490	416) 589-3618		
If patient confused or loses IV access - HOLD PCA and Treat Pain with			PMH			
	h					
mg IV / SC q	h prn.	APS Stoff	4151664-6420			
		141	416(064-6685			

		niversity Health Network	
		Doctor's Order Sheet	
	Ca	ardiac Investigation Unit	
	Po	ost Cardiac Catheterization Orders	al a second
	OR		
		PHYSICIAN'S ORDER AND SIGNATURE	AND LINES PARA
		Please check appropriate box(es) and complete orders as required)	
	2.	MEDICATION GIVEN DURING CARDIAC CATHETERIZATION Heparin	
		NTHERAPY: Starl M: D5W to keep vain open (TKVO) OR Discontinue IV as per criteria in policy 3.50.013 TREATMENT: a) May have head of bed up 30 degrees.	
	6	b) Sandbag for hours. c) Remove dressing 24 hours after the procedure. RADIAL ARTERY APPROACH: a) Clamp time: Hemoband* 90 minutes. Radal Artery Clamp 90 minutes.	
_		 b) Elevate arm on pillow. c) May sit up. d) Blood pressure on oposite arm. e) Vital Signs q 15 minutes while clamp on arm (Blood Pressure, Colour sensation movement and warmth and Oxypen Saturation). f) Release clamp as per units protocol (check with department) g) Discharge patient with dressing and sing as as per units protocol (check with department) 	
20	7.		
		New Medications: a) Acetaminophen (Tylenol ⁴) (325-650 mg) mg po q 4 h pm b) Other:	
	8.	Discharge	
	Pm)	yacan's Sgrakue Deter / / Time	
	1	COMES: ORIGINAL - RETAININ CHART: YELLOW - PHARMACY	

Step Five:

For each failure mode, determine the potential effect on the patient

- likelihood of occurrence,
- Likelihood of detection
- Severity

Steps in the Process	Failure Mode	Failure Causes	Failure Effects	Likelihood of Occurrences (1-10)	Likelihood of detection (1-10)	Severity (1-10)	Risk Profile Number	Actions to Reduce
1								
2								

Likelihood of Occurrence

1 = it is highly unlikely / never happened here before 5 = it is very likely / it happens here frequently

Likelihood of Detection

 $1 = it is very likely \dots 5 = it is highly unlikely$

Severity

 $1 = no patient harm \dots 5 = permanent patient harm or death$

Steps in the Process	Failure Mode	Failure Causes	Failure Effects	Likelihood of Occurrence (1-5)	Likelihood of detection (1-5)	Severity (1-5)	Risk Profile Number	Actions to Reduce
1								
2								

Step Six:

Determine which failures to work on

- Calculate the Risk Priority Number (RPN)

 Multiply the three scores obtained for likelihood of occurrences, detection, and severity
 - Identify the failure modes with the the top 10 RPNs

Step Seven:

Use RPNs to plan improvement efforts

Failure modes with high RPNs are usually the most important parts of the process to concentrate improvement efforts.

If the failure mode is likely to occur:

- Evaluate causes to determine if any can be eliminated.
 - What safeguards are in place?
 - Do the safeguards work?
 - What would have to go wrong for this failure to occur?
 - Why wouldn't the failure be caught and corrected before it reached to patient?

If the failure mode is likely to occur (cont.):

- Consider using a force function.
 Discontinue medications
- Add a verification step.
- Modify other processes that contribute to causes.

Design and Implement Improvement Strategies to Prevent Failures.

- Eliminate the chance for errors.
- Make it easier for people to do the right thing.
- Identify errors quickly and take appropriate action.

How to use the FMEA tool

- To evaluate the potential impact of changes under consideration.
 - Teams can 'verbally simulate' a change before implementing in patient care areas
- To monitor and track improvement over time.
 - Use total RPN to set a goal for improvement (i.e. improve by 50%)



Case Study Worksheet

Steps in the Process	Failure Mode	Failure Causes	Failure Effects	Likelihood of Occurrences (1-5)	Likelihood of detection (1-5)	Severity (1-5)	Risk Profile Number (RPN)	Actions to Reduce
1								
2								
3								
							TOTAL RPN (Sum of all RPNs):	

Questions?